| MO |
Report |
Adjusted diluted EPS (Q2) |
BEAT |
pred ~$1.51 vs. cons ~$1.49 |
MEDIUM |
| MO |
Report |
Adjusted domestic cigarette shipment volume (YoY) |
BEAT |
pred ~-4% vs. cons ~-5% |
MEDIUM |
| MO |
Report |
Oral tobacco adjusted OCI growth (YoY) |
MISS |
pred ~+1% vs. cons ~+3% |
LOW |
| MO |
Guide |
FY2026 adjusted diluted EPS guidance |
UNCHANGED |
guide ~$5.56-$5.72 (mid ~$5.64) vs. cons ~$5.64 (FY2026) |
MEDIUM |
| MO |
Guide |
Cigarette industry volume decline outlook |
BETTER |
guide ~-4% to -5% vs. cons ~-6% (FY2026 industry) |
MEDIUM |
| MO |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.0% |
— |
MEDIUM |
| MO |
Return |
5-day cumulative residual |
+0.5% (FADE) |
A modest EPS beat plus continued cigarette-volume moderation supports a small positive day-1 reaction, but the stock is at multi-year highs (~$75, +26% YoY) and already ran ~4% into the print, so much of the good news is priced. Critically, management is likely to reaffirm (not raise) FY2026 EPS despite a hot H1 — the out-period math implies an implicit H2 deceleration, so consensus for Q3/Q4 does not move up and the beat gets absorbed. Combined with soft oral/on! momentum and first-time-CEO conservatism, gains fade over the week. |
MEDIUM |